Previous close | 1.4500 |
Open | 1.6000 |
Bid | 0.9500 |
Ask | 2.9500 |
Strike | 20.00 |
Expiry date | 2024-07-19 |
Day's range | 1.4500 - 1.6000 |
Contract range | N/A |
Volume | |
Open interest | 63 |
Despite Revenue Near Estimates, Losses Exceed Expectations
Fulgent Genetics (FLGT) delivered earnings and revenue surprises of 96.97% and 1.90%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
EL MONTE, Calif., May 03, 2024--Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent," or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its first quarter ended March 31, 2024.